Ginkgo Bioworks Holdings, Inc. (DNA) stock
DNANYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/3012% below fair value
$8.50−1.11 (-11.55%)
Close on Nov 16, 2026Market cap $572.39MP/E –Yield –
Ginkgo Bioworks r&d expenses
Research and development expenses are spending on new products and technology.
Ginkgo Bioworks's R&D Expenses for the twelve months ending Jun 30, 2026 was $215.61M, down 22.4% year over year. For fiscal 2025 it was $243.77M, down 42.5% from the year before. The highest annual figure on record is $1.15B in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $243.77M | -42.5% |
| FY2024 | Dec 31, 2024 | $424.06M | -27.0% |
| FY2023 | Dec 31, 2023 | $580.62M | -44.8% |
| FY2022 | Dec 31, 2022 | $1.05B | -8.4% |
| FY2021 | Dec 31, 2021 | $1.15B | +619.6% |
| FY2020 | Dec 31, 2020 | $159.77M | +65.9% |
| FY2019 | Dec 31, 2019 | $96.30M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $46.21M | -13.4% |
| Q1 FY2026 | Mar 31, 2026 | $49.92M | -29.6% |
| Q4 FY2025 | Dec 31, 2025 | $50.13M | -34.4% |
| Q3 FY2025 | Sep 30, 2025 | $69.35M | -9.9% |
| Q2 FY2025 | Jun 30, 2025 | $53.37M | -60.2% |
| Q1 FY2025 | Mar 31, 2025 | $70.92M | -48.0% |
| Q4 FY2024 | Dec 31, 2024 | $76.38M | -34.7% |
| Q3 FY2024 | Sep 30, 2024 | $77.01M | -50.8% |
| Q2 FY2024 | Jun 30, 2024 | $134.22M | -7.0% |
| Q1 FY2024 | Mar 31, 2024 | $136.46M | -16.1% |
| Q4 FY2023 | Dec 31, 2023 | $117.04M | -34.1% |
| Q3 FY2023 | Sep 30, 2023 | $156.66M | -40.1% |
| Q2 FY2023 | Jun 30, 2023 | $144.28M | -50.3% |
| Q1 FY2023 | Mar 31, 2023 | $162.64M | -49.7% |
| Q4 FY2022 | Dec 31, 2022 | $177.55M | -82.0% |
| Q3 FY2022 | Sep 30, 2022 | $261.46M | +393.1% |
| Q2 FY2022 | Jun 30, 2022 | $290.06M | +457.5% |
| Q1 FY2022 | Mar 31, 2022 | $323.58M | +443.0% |
| Q4 FY2021 | Dec 31, 2021 | $985.03M | +1509.8% |
| Q3 FY2021 | Sep 30, 2021 | $53.02M | +47.0% |
| Q2 FY2021 | Jun 30, 2021 | $52.03M | – |
| Q1 FY2021 | Mar 31, 2021 | $59.59M | – |
| Q4 FY2020 | Dec 31, 2020 | $61.19M | – |
| Q3 FY2020 | Sep 30, 2020 | $36.07M | – |
See a number that looks wrong?